BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 17926797)

  • 1. Evolving role of novel targeted agents in renal cell carcinoma.
    Hutson TE; Figlin RA
    Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel therapeutics for metastatic renal cell carcinoma.
    Hutson TE; Figlin RA
    Cancer; 2009 May; 115(10 Suppl):2361-7. PubMed ID: 19402059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel targeted therapy for advanced renal carcinoma: trials in progress.
    Calabrò F; Sternberg CN
    Curr Opin Urol; 2010 Sep; 20(5):382-7. PubMed ID: 20625300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA; Puzanov I; Atkins MB
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Pouessel D; Culine S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting growth factor and antiangiogenic pathways in clear-cell renal cell carcinoma: rationale and ongoing trials.
    Hutson TE; Sonpavde G; Galsky MD
    Clin Genitourin Cancer; 2006 Dec; 5 Suppl 1():S31-9. PubMed ID: 17239282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
    Bukowski RM
    Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recent advancements in the treatment of renal cell carcinoma--focus on international guidelines].
    Biró K; Küronya Z
    Magy Onkol; 2010 Dec; 54(4):369-76. PubMed ID: 21163768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for metastatic renal cell carcinoma: a review.
    Athar U; Gentile TC
    Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 13. Pazopanib for the treatment of renal cancer.
    Al-Marrawi MY; Rini B
    Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second-line therapy for refractory renal-cell carcinoma.
    Zustovich F; Lombardi G; Nicoletto O; Pastorelli D
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):112-22. PubMed ID: 21944739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic therapy in renal cell cancer.
    Srinivasan R; Armstrong AJ; Dahut W; George DJ
    BJU Int; 2007 May; 99(5 Pt B):1296-300. PubMed ID: 17441927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic therapy for metastatic renal cell carcinoma.
    Kroog GS; Motzer RJ
    Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Renal cell carcinoma and antiangiogenic therapies].
    Pouessel D; Culine S; Verhoest G; Patard JJ
    Presse Med; 2008 Apr; 37(4 Pt 2):628-33. PubMed ID: 18035517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy for metastatic renal cell carcinoma: a home run or a work in progress?
    Rini BI; Bukowski RM
    Oncology (Williston Park); 2008 Apr; 22(4):388-96; discussion 396, 402-3, 476 passim. PubMed ID: 18472614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy in metastatic renal cell cancer.
    Ravaud A; Gross-Goupil M; Bellmunt J
    Semin Oncol; 2013 Aug; 40(4):472-81. PubMed ID: 23972711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.